Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | VNN1 | O95497 | 7/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545254 | 0.92 | GSK3B (0.51) | GSK3BVNN1CHEK1CCNE1CDK2 | |
| SCHEMBL13118960 | 0.91 | GSK3B (0.66) | GSK3BCCNE1CDK2 | |
| SCHEMBL13289048 | 0.89 | GSK3B (0.59) | GSK3BVNN1CHEK1CCNE1CDK2 | |
| SCHEMBL14301729 | 0.89 | GSK3B (0.55) | GSK3BVNN1CHEK1CCNE1CDK2 | |
| SCHEMBL14613311 | 0.85 | GSK3B (0.53) | GSK3BCHEK1CDK2 | |
| SCHEMBL13288814 | 0.84 | GSK3B (0.61) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL12953848 | 0.84 | GSK3B (0.61) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13305370 | 0.84 | GSK3B (0.61) | GSK3BVNN1CHEK1CCNE1CDK2 | |
| SCHEMBL13119228 | 0.84 | GSK3B (0.63) | GSK3BVNN1CCNE1CDK2 | |
| SCHEMBL13288837 | 0.83 | GSK3B (0.57) | GSK3BVNN1CHEK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | GSK3B 749/4885VNN1 3995/4885RBP4 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.